First-trimester Prediction of Preeclampsia

NCT ID: NCT02189148

Last Updated: 2019-07-23

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 7554 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-11-30
• Study Completion Date: 2018-03-31

Brief Summary

Preeclampsia is a complication of pregnancy related to adverse maternal and neonatal outcomes, including fetal growth restriction and perinatal death. Several measures are used or under investigation (low-dose aspirin, low-molecular weight heparin, calcium, folic acid, among others) for the prevention of preeclampsia. Unfortunately, most high-risk women who could benefit from those preventive measures are not identified until late in pregnancy. Recent evidences suggest that the investigators could identify women at risk of developing preeclampsia using a combination of serum and ultrasound biomarkers in the first-trimester of pregnancy. This screening test needs external validation. A first-trimester screening strategy will strengthen clinical research on preeclampsia and will contribute to the development of strategy combining the prediction and prevention of the disease and its related complications.

Detailed Description

Background: Preeclampsia (PE) is a placenta-mediated pregnancy complication related to adverse maternal and neonatal outcomes, including intra-uterine growth restriction (IUGR) and perinatal death. A growing body of evidence suggests that the preterm and severe forms of PE are associated with deep placentation disorders that occur early in gestation. Over the last decade, maternal characteristic and first-trimester biomarkers, including some that are already used for aneuploidy screening (PAPP-A) have been strongly related to the preterm and early forms of PE, suggesting that early prediction is possible. Preventive measures are actually recommended (low-dose aspirin; calcium) or under investigation (folic acid; low-molecular weight heparin; anti-oxidant) in high-risk women. However, only women with chronic disease or prior adverse pregnancy outcomes are eligible for these measures while most cases of PE occur in nulliparous women. Moreover, there are actually no clear guidelines for clinicians in Canada whose pregnant patients have one or several risk factors for preeclampsia (obesity, chronic hypertension, low PAPP-A, etc.). On the other hand, it has been suggested that prediction of PE, and particularly the most severe cases, is possible with high sensitivity and specificity by using a combination of anamnestic, biophysical, biochemical and ultrasonographic biomarkers using the web-based Fetal-Medicine Foundation (FMF) screening test. This suggests that a strategy of prediction and prevention of PE and other placenta-mediated complications is becoming possible for nulliparous women as well. However, certain major concerns must be addressed: 1) The FMF screening test has not been validated prospectively; 2) a controversy exists about the need and feasibility of Doppler ultrasound in the general population.

Objectives:

1. To validate the 11-13 week FMF screening test for early-onset PE and a composite of placenta-mediated outcomes (preterm PE, IUGR <3rd percentile, stillbirth); and

2. To compare the screening test with and without uterine artery (UtA) Doppler;

3. To explore the efficiency of new potential biomarkers (ADAM-12; Placental protein (PP) -13; placental and subplacental volume; placental vascularization) for prediction of PE in our population.

Methods: A multicenter prospective observational study of nulliparous women recruited between 11 3/7 - 13 6/7 weeks (maternal characteristics; BMI; Mean arterial pressure (MAP); PAPP-A; placental growth factor (PIGF); UtA Doppler…) and followed until delivery. Delivery and neonatal data will be collected through chart reviews. Detection rates for early-onset PE (primary outcome) and other adverse pregnancy outcomes will be measured using the 11-13 weeks FMF screening test with and without UtA Doppler results. A case-cohort study will be performed using stored serum samples and three-dimensional ultrasound volume acquired at the 11-13 weeks visit.

Feasibility and power calculation: We estimate a minimum incidence of early-onset PE of 0.7%. A minimum of 7,600 women will be necessary to demonstrate that the FMF screening test is at least 80% sensitive and 90% specific where it is expected that it will be 95% sensitive and 92% specific. We will have the power to detect an absolute difference of 15% in the detection rate between the different screening strategies (± Doppler). Recruitment will take 3.0 years. The overall study will take 5.0 years.

Expectations: First, our research will potentially provide a validated, highly sensitive and specific, and cheap tool to help clinicians' decision in the care of nulliparous women with risk factors for PE. In case of negative results, the clinician will have good evidence to reassure the patients facing abnormal maternal serum screening values. The validation of a first-trimester screening strategy will strengthen clinical research on PE providing new information on the natural evolution of the disease. Finally, this study will contribute to develop the optimal design for randomized trials aiming at the prevention of early-onset PE and other placenta-mediated complications of pregnancy.

Conditions

Preeclampsia; Severe Preeclampsia; Fetal Growth Restriction; Preterm Birth

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Cohort

Each participant will :

• give consent
• provide a blood sample (10 ml)
• be measured (weight and height for BMI calculation)
• undergo a blood pressure measurement
• have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)
• answer to a short questionnaire (5 pages)

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• gestational age between 11 3/7 and 13 6/7 weeks;
• nulliparous women (no previous delivery ≥ 20 weeks).

Exclusion Criteria

• pregnant women <18 years old at recruitment;
• multiple pregnancies;
• fetal congenital malformation;
• positive for HIV or hepatitis C or hepatitis B;
• negative fetal heart at recruitment;
• women planning a delivery outside the participating hospitals;
• women not able to provide an informed consent to the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

Laval University

OTHER

Sponsor Role: collaborator

CHU de Quebec-Universite Laval

OTHER

Sponsor Role: lead

Responsible Party

Emmanuel Bujold

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Emmanuel Bujold, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

CHU de Québec

François Audibert, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

St. Justine's Hospital

Locations

South Alberta Maternal Fetal Medicine Centre, University of Calgary

Calgary, Alberta, Canada

Sinai Health System, Mount Sinai Hospital

Toronto, Ontario, Canada

CHU Ste-Justine

Montreal, Quebec, Canada

CHU de Québec

Québec, Quebec, Canada

Countries

Canada

References

Guerby P, Audibert F, Johnson JA, Okun N, Giguere Y, Forest JC, Chaillet N, Masse B, Wright D, Ghesquiere L, Bujold E. Prospective Validation of First-Trimester Screening for Preterm Preeclampsia in Nulliparous Women (PREDICTION Study). Hypertension. 2024 Jul;81(7):1574-1582. doi: 10.1161/HYPERTENSIONAHA.123.22584. Epub 2024 May 6.

Reference Type: DERIVED

PMID: 38708601 (View on PubMed)

Related Links

http://www.crchudequebec.ulaval.ca/etudes/B14-05-2024.pdf

Prediction study at Centre de recherche du Centre Hospitalier Universitaire de Québec

Other Identifiers

B14-05-2024

Identifier Type: OTHER

Identifier Source: secondary_id

CIHR-MOP-133672

Identifier Type: -

Identifier Source: org_study_id